|
1) Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-60
|
|
|
|
2) Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194-8
|
|
|
|
|
|
3) Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407: 908-13
|
|
|
|
|
|
4) Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006; 116: 1983-93
|
|
|
|
|
|
5) Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004; 114: 57-66
|
|
|
|
|
|
6) Granado M, Priego T, Martín AI, et al. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005; 288: E486-92
|
|
|
|
|
|
7) Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B activation in human endothelial cells. Circulation. 2004; 109: 2221-6
|
|
|
|
|
|
8) Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001; 104: 1430-5
|
|
|
|
|
|
9) Nagaya N, Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol. 2003; 3: 146-51
|
|
|
|
|
|
10) Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001; 280: R1483-7
|
|
|
|
|
|
11) Matsumura K, Tsuchihashi T, Fujii K, et al. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension. 2002; 40: 694-9
|
|
|
|
|
|
12) Dornonville d l C, Lindstrom E, Norlen P, et al. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept. 2004; 120: 23-32
|
|
|
|
|
|
13) Akamizu T, Iwakura H, Ariyasu H, et al. Effects of ghrelin treatment on patients undergoing total hip replacement for osteoarthritis: different outcomes from studies in patients with cardiac and pulmonary cachexia. J Am Geriatr Soc. 2008; 56: 2363-5
|
|
|
|
|
|
14) Yamamoto K, Takiguchi S, Miyata H, et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery. 2010; 148: 31-8
|
|
|
|
|
|
15) Adachi S, Takiguchi S, Okada K, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology. 2010; 138: 1312-20
|
|
|
|
|
|
16) Hotta M, Ohwada R, Akamizu T, et al. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocr J. 2009; 56: 1119-28
|
|
|
|
|
17) Akamizu T, Iwakura H, Ariyasu H, et al. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol. 2008; 158: 491-8
|
|
|
|
|
|
18) Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89: 2832-6
|
|
|
|
|
|
19) Garcia JM, Boccia RV, Graham C, et al. A phase II, randomized, placebo-controlled, double blind study of the efficacy and safty of RC-1291 for the treatment of cancer-cachexia [abstract]. J Clin Oncol. 2007; 25: S25
|
|
|
|
|
|
20) Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008; 98: 300-8
|
|
|
|
|
|
21) Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001; 86: 5854-9
|
|
|
|
|
|
22) Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol. 2005; 16: 2111-8
|
|
|
|
|
|
23) Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005; 128: 1187-93
|
|
|
|
|
|
24) Kodama T, Ashitani J, Matsumoto N, et al. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulm Pharmacol Ther. 2008; 21: 774-9
|
|
|
|
|
|
25) Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000; 85: 4908-11
|
|
|
|
|
|
26) Asakawa A, Inui A, Fujimiya M, et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut. 2005; 54: 18-24
|
|
|
|
|
|
27) Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000; 141: 4325-8
|
|
|
|
|
|
28) Waseem T, Javaid-Ur-Rehman, Ahmad F, et al. Role of ghrelin axis in colorectal cancer: a novel association. Peptides. 2008; 29: 1369-76
|
|
|
|
|
|
29) Wu R, Dong W, Zhou M, et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med. 2007; 176: 805-13
|
|
|
|
|
|
30) Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004; 110: 3674-9
|
|
|
|
|
|
31) Wu R, Zhou M, Das P, et al. Ghrelin inhibits sympathetic nervous activity in sepsis. Am J Physiol Endocrinol Metab. 2007; 293: E1697-702
|
|
|
|
|
|
32) Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160: 1856-61
|
|
|
|
|
|
33) Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 170: 879-82
|
|
|
|
|
|
34) Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001; 23: 2034-8
|
|
|
|
|
|
35) Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003; 9: 774-8
|
|
|
|
|
|
36) Gadek JE. Adverse effects of neutrophils on the lung. Am J Med. 1992; 92: 27S-31S
|
|
|
|
|
|
37) Yamato M, Sakata I, Wada R, et al. Exogenous administration of octanoic acid accelerates octanoylated ghrelin production in the proventriculus of neonatal chicks. Biochem Biophys Res Commun. 2005; 333: 583-9
|
|
|
|
|
|
38) Ashitani J, Matsumoto N, Nakazato M. Effect of octanoic acid-rich formula on plasma ghrelin levels in cachectic patients with chronic respiratory disease. Nutr J. 2009; 8: 25
|
|
|
|
|
|
39) Andreyev HJ, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies？ Eur J Cancer. 1998; 34: 503-9
|
|
|
|
|
|
40) Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980; 69: 491-7
|
|
|
|
|
|
41) Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005; 90: 2920-6
|
|
|
|
|
|
42) Garcia JM, Cata JP, Dougherty PM, et al. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology. 2008; 149: 455-60
|
|
|
|
|
|
43) Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010; 151: 3773-82
|
|
|
|
|